Novel three-step pretargeted radioimmunotherapy offers safe, effective treatment
Researchers at Memorial Sloan Kettering Cancer Center in New York City and Massachusetts Institute of Technology in Boston have developed a new, three-step system that uses nuclear medicine to target and eliminate colorectal cancer. In this study with a mouse model, researchers achieved a 100-percent cure rate—without any treatment-related toxic effects. The study is reported in the November featured article in The Journal of Nuclear Medicine.
Until now, radioimmunotherapy (targeted therapy) of solid tumors using antibody-targeted radionuclides has had limited therapeutic success. “This research is novel because of the benchmarks reached by the treatment regimen, in terms of curative tumor doses, with non-toxic secondary radiation to the body’s normal tissues,” explains Steven M. Larson, MD, and Sarah Cheal, PhD, of Memorial Sloan Kettering Cancer Center. “The success in murine tumor models comes from the unique quality of the reagents developed by our group, and the reduction to practice methodology, including a theranostic approach that can be readily transferred, we believe, to patients.”
Theranostics, a term derived from therapy and diagnostics, is the use of a single agent to both diagnose and treat disease. The theranostic agent first finds the cancer cells, then destroys them, leaving healthy cells unharmed—minimizing side effects and improving quality of life for patients.
In this study, the glycoprotein A33 (GPA33), an antigen found on over 95 percent of primary and metastatic human colorectal cancers, was targeted with a bispecific antibody for A33 tumor antigen and a second antibody for a small-molecule radioactive hapten, a complex of lutetium-177 (177Lu) and S-2-(4-aminobenzyl)1,4,7,10-tetraazacyclododecane tetra-acetic acid (177Lu-DOTA-Bn).
The DOTA-pretargeted radioimmunotherapy (PRIT) strategy was tested on a mouse model. In randomly selected mice undergoing treatment, serial SPECT/CT imaging was used to monitor treatment response and calculate radiation-absorbed doses to tumors. All the DOTA-PRIT–treated animals tolerated the treatment well, and all 9 assessed mice had no trace of cancer remaining upon microscopic examination. There was also no detectable radiation damage to critical organs, including bone marrow and kidneys.
The 100-percent cure rate in the mouse model is a promising preliminary finding that suggests that anti-GPA33-DOTA-PRIT will be a potent radioimmunotherapy regimen for GPA33-positive colorectal cancer tumors in humans.
According to the Centers for Disease Control and Prevention, colorectal cancer is the third most common cancer affecting both men and women. Each year, approximately 140,000 new cases are diagnosed in the United States and 50,000 people die of the disease.
The applications of this nuclear medicine treatment protocol could extend to other cancers as well. Larson and Cheal state, “If clinically successful, our approach will expand the repertoire of effective treatments for oncologic patients. The system is designed as a ‘plug and play’ system, which allows for the use of many fine antibodies targeting human tumor antigens and is applicable, in principle, to virtually all solid and liquid tumors in man.” They add, “There is a huge unmet need in oncology, especially for the solid tumors, for curative treatments for advanced disease. This includes, colon, breast, pancreas, melanoma, lung, and esophageal, to name a few.”
The Latest on: Colorectal cancer
- Dying behind bars: 33-year-old inmate’s stage 4 cancer going untreated in Alabama prisonon February 16, 2020 at 7:00 am
But his life was upended when he found out that he was dying. In April 2019, the 33-year-old Odenville man was diagnosed with stage 4 colon cancer that had spread to his liver. He underwent several ...
- GI Bleeding on Oral Anticoagulants in Atrial Fib Foremost a Colon Cancer Red Flagon February 14, 2020 at 12:59 pm
Bleeding from the lower gastrointestinal (GI) tract shouldn't be seen as simply a manageable adverse effect of oral anticoagulation (OAC) for atrial fibrillation (AF). Rather, it's a red flag that the ...
- Colorectal Cancer Screening Market Healthcare, Clinical Reviews, Survey Reports forecast 2019 to 2024on February 14, 2020 at 1:00 am
Colorectal Cancer Screening market has been thoroughly scrutinized and then carefully demarcated by geographic locations which are based on major economic regions and their topographical regions.
- Let's Talk About Colorectal Cancer Stageson February 13, 2020 at 11:21 am
If you’ve received a colorectal cancer diagnosis, the first order of business for your doctor is to figure out what stage it is—in other words, determining if the cancer has spread to other parts of ...
- CUL4B contributes to cancer stemness by repressing tumor suppressor miR34a in colorectal canceron February 13, 2020 at 11:19 am
Given that colorectal cancer stem cells (CCSCs) play key roles in the tumor dormancy, metastasis, and relapse, targeting CCSCs is a promising strategy in cancer therapy. Here, we aimed to identify the ...
- Machine Learning Algorithms for Predicting the Recurrence of Stage IV Colorectal Cancer After Tumor Resectionon February 13, 2020 at 2:10 am
The aim of this study is to explore the feasibility of using machine learning (ML) technology to predict postoperative recurrence risk among stage IV colorectal cancer patients. Four basic ML ...
- 'Watch & Wait' in Rectal Cancer Doesn't Compromise Outcomeson February 13, 2020 at 1:14 am
"In the present study, the vast majority of patients (97%) with regrowth after W&W were able to undergo a curative treatment for local regrowth," say researchers led by Marit van der Sande, MD, the ...
- Let's Talk About Colorectal Cancer Causeson February 11, 2020 at 3:04 pm
If you have colorectal cancer (or know someone who does), you might be wondering, why me? That’s a great question, and one that researchers are exploring at this very minute. Because while we have ...
- Younger patients could get colon cancer screening covered by insurance under Colorado House billon February 10, 2020 at 12:00 pm
When he woke up, he found out he had stage 4 cancer, which likely had been growing for at least five years. Wilson, of Greenwood Village, was diagnosed at 48, making him part of the small but growing ...
- GI bleeding may signal colon cancer in patients on blood thinnerson February 7, 2020 at 2:01 pm
Gastrointestinal bleeding in patients taking blood thinners for an irregular heartbeat should prompt doctors to check for colon cancer, a new study advises. Researchers looked at more than 125,000 ...
via Google News and Bing News